Silo Pharma, Inc. (SILO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on December 29, 2025, regarding events occurring on December 24, 2025. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol "SILO".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes and Listing Status
- Non-Compliance: The Company failed to meet Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for 30 consecutive business days, by the initial deadline of December 24, 2025.
- Extension Granted: Nasdaq granted an extension of 180 calendar days, providing a new compliance deadline of June 22, 2026.
- Current Trading Status: The extension has no immediate effect on trading; the Company's common stock will continue to trade on The Nasdaq Capital Market.
Outlook, Management Commentary, and Risks
Management intends to monitor the closing bid price and may implement a reverse stock split if necessary to regain compliance. The Company has indicated its intention to cure the deficiency during the second compliance period.
Risks and Contingencies:
- If the bid price does not close at or above $1.00 per share for 10 consecutive business days prior to June 22, 2026, Nasdaq will notify the Company of delisting.
- In the event of delisting, the Company may appeal the determination to a Hearings Panel.
Key Facts for Investor Verification
- Verify the current closing bid price of SILO stock relative to the $1.00 threshold.
- Monitor for any future announcements regarding the implementation of a reverse stock split.
- Confirm the final compliance deadline of June 22, 2026, to avoid potential delisting.
- Review the Company's financial statements for liquidity constraints that may impact the ability to execute a reverse stock split or other capital raising activities.